Who We Are

MabVax is a clinical stage biotechnology company. We have discovered and are developing novel human antibody based products for the diagnosis and treatment of metastatic solid tumor cancers. We have created a platform technology to discover antibodies from patient immune responses against their cancers.
We now have a portfolio of fully human antibodies that are being developed to address unmet medical needs in several difficult to treat cancers such as pancreatic, small cell lung, sarcoma, ovarian, and breast cancer.
Our lead antibody development program is HuMab-5B1 and we started two clinical trials this year with a therapeutic agent (MVT-5873) and as a new generation PET imaging product (MVT-2163). In addition, we have identified a radioimmunotherapy agent (MVT-1075) and we plan to file an Investigational New Drug Application (NDA) with the FDA later this year.

Clinical Trials

MVT-5873: MVT-5873 (HuMab-5B1) is our therapeutic antibody. The Phase I trial began in the first quarter of this year to evaluate the safety, tolerability and pharmacokinetics as a single agent or in combination with a standard of care chemotherapy. The trial is underway in subjects with metastatic pancreatic cancer or other CA19-9 positive malignancies.
Learn More > 
MVT-2163: MVT-2163 (89Zr-HuMab-5B1) is our positron emission tomography (PET) imaging agent. The Phase I trial began in the second quarter of this year at Memorial Sloan Kettering Cancer Center. In preclinical models this imaging agent demonstrated high-resolution images of tumors in xenograft animal models, and is now being evaluated in human clinical trials as an important new tool to aid in the diagnosis, monitoring and assessment of patients with pancreatic cancer. MVT-2163 is planned for evaluation as companion diagnostic with MVT-5873.
Learn More > 

News and Events

Upcoming Events
February 13th, 2017
MabVax CEO David Hansen to present at 2017 BIO CEO & Investor Conference in New York.

Stock News Now Interview with MabVax Theraputics's CEO David Hansen.
Click Here to view the interview >

MabVax Therapeutics Inc.  releases most current Shareholder Letter >